MX2009008665A - Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa. - Google Patents

Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa.

Info

Publication number
MX2009008665A
MX2009008665A MX2009008665A MX2009008665A MX2009008665A MX 2009008665 A MX2009008665 A MX 2009008665A MX 2009008665 A MX2009008665 A MX 2009008665A MX 2009008665 A MX2009008665 A MX 2009008665A MX 2009008665 A MX2009008665 A MX 2009008665A
Authority
MX
Mexico
Prior art keywords
kinase inhibitors
synthesis
group
aminothiazole compounds
inhibitors
Prior art date
Application number
MX2009008665A
Other languages
English (en)
Inventor
Alain Moussy
Philippe Reginault
Francois Bellamy
Anne Lermet
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of MX2009008665A publication Critical patent/MX2009008665A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

La presente invención se refiere a un procedimiento industrial para preparar compuestos farmacéuticos de formula I: (ver fórmula (I)) que son útiles como determinados inhibidores de tirosina quinasa y más particularmente como inhibidores de c-kit y bcr-abl. Los grupos R1 y R2, idénticos o diferentes, representan cada uno un átomo de hidrógeno o halógeno, un alquilo, un alcoxi, un trifluorometilo, un amino, un alquilamino, un dialquilamino, un grupo solubilizante; m es 0-5 y n es 0-4; el grupo R3 representa un grupo arilo o heteroarilo como se describe en las reivindicaciones de la presente.
MX2009008665A 2007-02-13 2008-02-13 Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa. MX2009008665A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88958707P 2007-02-13 2007-02-13
PCT/EP2008/051704 WO2008098949A2 (en) 2007-02-13 2008-02-13 Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2009008665A true MX2009008665A (es) 2009-08-21

Family

ID=39332208

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008665A MX2009008665A (es) 2007-02-13 2008-02-13 Procedimiento para la sintesis de compuestos de 2-aminotiazol como inhibidores de quinasa.

Country Status (23)

Country Link
US (3) US8153792B2 (es)
EP (2) EP2118099B1 (es)
JP (2) JP5568312B2 (es)
KR (1) KR20090110851A (es)
CN (2) CN101657446B (es)
AR (1) AR065337A1 (es)
AT (1) ATE515506T1 (es)
AU (1) AU2008214679A1 (es)
BR (1) BRPI0807626B1 (es)
CA (2) CA2970628C (es)
ES (2) ES2369617T3 (es)
HR (2) HRP20110709T1 (es)
IL (1) IL200320A0 (es)
MA (1) MA31180B1 (es)
MX (1) MX2009008665A (es)
NZ (1) NZ578944A (es)
PL (2) PL2118099T3 (es)
RU (2) RU2456285C2 (es)
SI (2) SI2366703T1 (es)
TN (1) TN2009000342A1 (es)
TW (1) TWI406862B (es)
WO (1) WO2008098949A2 (es)
ZA (1) ZA200905981B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4726486B2 (ja) 2002-08-02 2011-07-20 アブ サイエンス 2−(3−アミノアリール)アミノ−4−アリール−チアゾールおよびそれらのc−kit阻害薬としての使用法
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
US20120302577A1 (en) 2010-01-28 2012-11-29 Ab Science Treatment of gist with masitinib
TW201130830A (en) 2010-02-01 2011-09-16 Ab Science Combined treatment of pancreatic cancer with gemcitabine and masitinib
AR080380A1 (es) 2010-03-09 2012-04-04 Ab Science Tratamiento de la demencia tipo alzheimer con masitinib
AR080933A1 (es) 2010-04-20 2012-05-16 Ab Science Tratamiento de esclerosis multiple con masitinib
AR081772A1 (es) 2010-06-02 2012-10-17 Ab Science Tratamiento de la artritis reumatoide con masitinib
US10045978B2 (en) 2010-11-05 2018-08-14 Ab Science Treatment of mastocytosis with masitinib
WO2012059526A1 (en) 2010-11-05 2012-05-10 Ab Science Treatment of mastocytosis with masitinib
US9078894B2 (en) 2011-02-04 2015-07-14 Ab Science Treatment of severe persistant asthma with masitinib
AR085934A1 (es) 2011-04-08 2013-11-06 Ab Science Tratamiento de mieloma multiple con masitinib
BR112015007144A2 (pt) 2012-10-04 2017-12-12 Ab Science uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
WO2015082496A1 (en) 2013-12-02 2015-06-11 Ab Science Use of masitinib for treatment of colorectal cancer
EP2886543A1 (en) 2013-12-18 2015-06-24 Sandoz Ag Crystalline form of mastinib mesylate
WO2015185958A1 (en) 2014-06-02 2015-12-10 Ab Science Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer
CN105585556A (zh) * 2014-11-13 2016-05-18 连云港杰瑞药业有限公司 一种伊马替尼的合成方法
WO2017016512A1 (zh) * 2015-07-29 2017-02-02 苏州晶云药物科技有限公司 马赛替尼甲磺酸盐的新晶型及其制备方法
JP6801892B2 (ja) 2015-10-05 2020-12-16 エービー サイエンス マシチニブによる重度の全身性肥満細胞症の治療
SI3240538T1 (sl) 2016-03-25 2022-02-28 Ab Science Uporaba masitiniba za zdravljenje subpopulacije bolnikov z amiotrofično lateralno sklerozo
CN110678464A (zh) * 2017-03-31 2020-01-10 桑多斯股份公司 马赛替尼的晶型
US10696638B2 (en) 2017-12-26 2020-06-30 Industrial Technology Research Institute Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same
WO2021099616A1 (en) 2019-11-22 2021-05-27 Ab Science Masitinib for the treatment of sickle cell disease
EP3831384A1 (en) 2019-12-02 2021-06-09 AB Science Use of masitinib for the treatment of eosinophilic asthma
KR20220143020A (ko) 2020-02-20 2022-10-24 에이비 사이언스 다발 경화증 환자 하위집단의 치료를 위한 마시티닙
AU2021253688A1 (en) 2020-04-10 2022-10-27 Ab Science Use of masitinib for the treatment of coronavirus disease 2019 (COVID-19)
CN116963736A (zh) 2020-12-16 2023-10-27 Ab科学有限公司 马赛替尼用于治疗阿尔茨海默病
KR20240008875A (ko) 2021-05-17 2024-01-19 에이비 사이언스 거세-저항성 전립선암의 치료를 위한 마시티닙
CN115850258A (zh) * 2022-12-27 2023-03-28 东北林业大学 一种马赛替尼的合成方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299087A (en) 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
RU2249591C2 (ru) * 1997-05-22 2005-04-10 Дж.Д. Серл Энд Ко. 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB9718913D0 (en) * 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
HUP0004512A3 (en) * 1997-10-27 2003-01-28 Agouron Pharmaceuticals Inc La 4-aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
US6114365A (en) * 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
SK4772002A3 (en) * 1999-09-10 2002-11-06 Merck & Co Inc Tyrosine kinase inhibitors, pharmaceutical composition containing the same and their use
JP2004530722A (ja) 2001-06-29 2004-10-07 アブ サイエンス 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法
DE60216281T2 (de) 2001-06-29 2007-07-05 Ab Science Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のc−kit阻害剤
JP2005503361A (ja) 2001-06-29 2005-02-03 アブ サイエンス 肥満細胞症治療のための強力で選択的かつ非毒性のc−kit阻害剤の使用
WO2003002107A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms)
WO2003002109A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
US20030091974A1 (en) 2001-06-29 2003-05-15 Alain Moussy Method for screening compounds capable of depleting mast cells
PT1401416E (pt) 2001-06-29 2007-02-28 Ab Science Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
EP1401412A2 (en) 2001-06-29 2004-03-31 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis
EP1401415B1 (en) 2001-06-29 2006-06-21 AB Science Use of n-phenyl-2-pyrimidine-amine derivatives for treating inflammatory diseases
DE60227701D1 (de) 2001-09-20 2008-08-28 Ab Science Die verwendung von c-kithemmern zur förderung des haarwuchses
DE60225590T2 (de) 2001-09-20 2008-09-25 Ab Science C-kithemmer zur behandlung von bakteriellen infektionen
CA2461183A1 (en) 2001-09-20 2003-05-15 Ab Science Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases
ATE334693T1 (de) 2002-02-27 2006-08-15 Ab Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
CA2477726A1 (en) 2002-02-27 2003-09-04 Ab Science Use of tyrosine kinase inhibitors for treating substance use disorders
PL373842A1 (en) * 2002-05-29 2005-09-19 Amgen Inc. 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders
JP4726486B2 (ja) * 2002-08-02 2011-07-20 アブ サイエンス 2−(3−アミノアリール)アミノ−4−アリール−チアゾールおよびそれらのc−kit阻害薬としての使用法
SE0202462D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel use
WO2004072068A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JP2006519220A (ja) 2003-02-27 2006-08-24 アブ サイエンス 異なる型の肥満細胞症に適合可能なテイラーメイド治療方法
FR2854158B1 (fr) * 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
EP1651648A4 (en) * 2003-07-29 2009-09-02 Irm Llc COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
ATE395052T1 (de) 2003-08-15 2008-05-15 Ab Science Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes
US7363881B2 (en) 2003-11-06 2008-04-29 Nova-Tech Engineering, Inc. Beak treatment with tongue protection
JPWO2005063709A1 (ja) 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
US7650848B2 (en) * 2004-02-17 2010-01-26 University Of Florida Research Foundation, Inc. Surface topographies for non-toxic bioadhesion control
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
TW200702876A (en) * 2005-07-04 2007-01-16 Avermedia Tech Inc Projector device capable of sychronously encoding audio and video to become AV sychronous paly file

Also Published As

Publication number Publication date
EP2118099A2 (en) 2009-11-18
CA2970628C (en) 2019-08-27
ZA200905981B (en) 2010-11-24
CA2970628A1 (en) 2008-08-21
CN103342701A (zh) 2013-10-09
SI2366703T1 (sl) 2014-10-30
BRPI0807626A2 (pt) 2014-11-25
TWI406862B (zh) 2013-09-01
JP2013177437A (ja) 2013-09-09
AR065337A1 (es) 2009-06-03
PL2118099T3 (pl) 2011-12-30
RU2491286C1 (ru) 2013-08-27
US8940894B2 (en) 2015-01-27
US20130289045A1 (en) 2013-10-31
TN2009000342A1 (en) 2010-12-31
AU2008214679A1 (en) 2008-08-21
WO2008098949A2 (en) 2008-08-21
TW200848419A (en) 2008-12-16
JP2010518141A (ja) 2010-05-27
EP2366703B1 (en) 2014-07-30
US8492545B2 (en) 2013-07-23
CN101657446A (zh) 2010-02-24
HRP20110709T1 (hr) 2011-11-30
ES2522169T3 (es) 2014-11-13
CA2677586C (en) 2017-07-25
MA31180B1 (fr) 2010-02-01
US20100121063A1 (en) 2010-05-13
US20120196871A1 (en) 2012-08-02
ES2369617T3 (es) 2011-12-02
CN103342701B (zh) 2016-09-21
JP5784073B2 (ja) 2015-09-24
SI2118099T1 (sl) 2011-11-30
EP2366703A1 (en) 2011-09-21
PL2366703T3 (pl) 2015-02-27
WO2008098949A3 (en) 2008-10-02
HRP20140986T1 (hr) 2014-11-21
CA2677586A1 (en) 2008-08-21
RU2456285C2 (ru) 2012-07-20
US8153792B2 (en) 2012-04-10
NZ578944A (en) 2011-03-31
KR20090110851A (ko) 2009-10-22
JP5568312B2 (ja) 2014-08-06
IL200320A0 (en) 2010-04-29
CN101657446B (zh) 2013-05-15
EP2118099B1 (en) 2011-07-06
ATE515506T1 (de) 2011-07-15
RU2009132186A (ru) 2011-03-20
BRPI0807626B1 (pt) 2022-03-03

Similar Documents

Publication Publication Date Title
TN2009000342A1 (en) Process for the synthesis of 2- aminothiazole compounds as kinase inhibitors
SI1711481T2 (sl) Postopek za pripravo 2-aminotiazoli-5-aromatiäśnih karboksamidov kot kinazni inhibitorji
HK1110588A1 (en) Novel phenylaminopyrimidine derivatives as inhibitors of bcr-abl kinase
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
UY30050A1 (es) Derivados de pirimido-oxazinil-fenilo, sales de los mismos, composiciones, preparaciones y aplicaciones
EA200870192A1 (ru) Новые серосодержащие производные циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназ
MX2009011213A (es) Derivados de triazolopiridina carboxamida y triazolopirimidina carboxamida, su preparacion y su aplicacion terapeutica.
DE602007009085D1 (de) Neues verfahren zur synthese von 2-aminooxazolverbindungen
TW201129556A (en) Novel antiplatelet agent
TNSN08276A1 (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
WO2005076990A3 (en) Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
ATE431333T1 (de) Amino-propanolderivate
RS51661B (en) NEW DIOSMETHINE DERIVATIVES, THE PROCEDURE FOR THEIR MAKING AND THE PHARMACEUTICAL MIXTURES CONTAINING THEM
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
TW200738685A (en) Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
TW200609223A (en) Process for the preparation of n-piperidino-1,5-diphenylpyrazole-3-carboxamide derivatives
MX2012000094A (es) Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su uso farmaceutica como inhibidores de fosforilacion de akt (pkb).
ATE513818T1 (de) Chinazolinonderivate als tubulinpolymerisationshemmer
SE0403085D0 (sv) Novel componds
JO3248B1 (ar) عملية لتحضير إنزيمات مثبطة من نوع c-fms
ATE364384T1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
SE0403086D0 (sv) Compounds
MY150988A (en) Novel derivatives of ( bridged piperazinyl)-1-alkanone and use thereof as p75 inhibitors
TN2014000519A1 (en) Pyrimidinone derivatives as antimalarial agents

Legal Events

Date Code Title Description
FG Grant or registration